Literature DB >> 26226095

Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis.

Sumeet K Asrani1.   

Abstract

Noninvasive methods are increasingly used for the assessment of liver fibrosis. Two categories of markers include serum-based markers (biologic properties) or ultrasound and magnetic resonance imaging-based techniques that use the principles of elastography (physical properties) to indirectly assess liver fibrosis. Serum markers can be either direct or indirect markers of the fibrosis process. Common elastography-based studies include vibration-controlled transient elastography, point shear wave elastography, and 2-dimensional shear wave elastography and magnetic resonance elastography. A common theme among all techniques is the inability to accurately differentiate between minimal or moderate stages of fibrosis but superior performance in identifying subjects with cirrhosis or normal liver parenchyma. Noninvasive markers may also serve as prognostic tools to course the natural history of chronic liver disease as well as identify cirrhotic patients at highest risk of future decompensation. Further research is needed to identify the role of noninvasive markers in following asymptomatic individuals, especially in patients with nonalcoholic fatty liver disease.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ARFI; BARD; Elastography; Imaging; Liver Cirrhosis; Liver Stiffness; Magnetic Resonance Imaging; NAFLD Fibrosis Score; SWE; Serum Markers; Shear Wave; TE

Mesh:

Substances:

Year:  2015        PMID: 26226095     DOI: 10.1016/j.cgh.2015.07.030

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  12 in total

1.  Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer.

Authors:  M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2016-01-19       Impact factor: 8.171

2.  Liver fibrosis: stretched exponential model outperforms mono-exponential and bi-exponential models of diffusion-weighted MRI.

Authors:  Nieun Seo; Yong Eun Chung; Yung Nyun Park; Eunju Kim; Jinwoo Hwang; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2018-02-05       Impact factor: 5.315

3.  Editorial: Magnetic Resonance Elastography and Non-Alcoholic Fatty Liver Disease: Time for an Upgrade?

Authors:  Avegail Flores; Sumeet K Asrani
Journal:  Am J Gastroenterol       Date:  2016-07       Impact factor: 10.864

4.  Derivation and Validation of a Model to Predict Clinically Significant Portal Hypertension Using Transient Elastography and FIB-4.

Authors:  Bubu A Banini; Samarth Patel; Jonathan W Yu; Le Kang; Christopher Bailey; Brian J Strife; Mohammad S Siddiqui; Vaishali Patel; Scott C Matherly; Hannah Lee; Shawn Lewis; Reena Cherian; Richard T Stravitz; Velimir Luketic; Arun J Sanyal; Richard K Sterling
Journal:  J Clin Gastroenterol       Date:  2022-01-10       Impact factor: 3.174

5.  Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Geraldine J Ooi; Paul R Burton; Lisa Doyle; John M Wentworth; Prithi S Bhathal; Ken Sikaris; Michael A Cowley; Stuart K Roberts; William Kemp; Arul Earnest; Paul E O'Brien; Wendy A Brown
Journal:  Obes Surg       Date:  2017-06       Impact factor: 4.129

6.  Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.

Authors:  Veeral H Ajmera; Edward R Cachay; Christian B Ramers; Shirin Bassirian; Seema Singh; Richele Bettencourt; Lisa Richards; Gavin Hamilton; Michael Middleton; Katie Fowler; Claude Sirlin; Rohit Loomba
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

7.  Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.

Authors:  Cyrielle Caussy; Mosab H Alquiraish; Phirum Nguyen; Carolyn Hernandez; Sandra Cepin; Lynda E Fortney; Veeral Ajmera; Ricki Bettencourt; Summer Collier; Jonathan Hooker; Ethan Sy; Emily Rizo; Lisa Richards; Claude B Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2018-02-19       Impact factor: 17.425

Review 8.  MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.

Authors:  Parambir S Dulai; Claude B Sirlin; Rohit Loomba
Journal:  J Hepatol       Date:  2016-06-14       Impact factor: 25.083

9.  Proteome-based identification of apolipoprotein A-IV as an early diagnostic biomarker in liver fibrosis.

Authors:  Pei-Wen Wang; Yu-Ching Hung; Tung-Ho Wu; Mu-Hong Chen; Chau-Ting Yeh; Tai-Long Pan
Journal:  Oncotarget       Date:  2017-10-06

10.  Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease.

Authors:  Marcin Krawczyk; Simone Zimmermann; Georg Hess; Robert Holz; Marc Dauer; Jochen Raedle; Frank Lammert; Frank Grünhage
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.